» Articles » PMID: 25329392

Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population

Overview
Journal PLoS One
Date 2014 Oct 21
PMID 25329392
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

The CYP2D6 enzyme is one of the most important members of the cytochrome P450 superfamily. This enzyme metabolizes approximately 25% of currently prescribed medications. The CYP2D6 gene presents a high allele heterogeneity that determines great inter-individual variation. The aim of this study was to evaluate the variability of CYP2D6 alleles, genotypes and predicted phenotypes in Brazilians. Eleven single nucleotide polymorphisms and CYP2D6 duplications/multiplications were genotyped by TaqMan assays in 1020 individuals from North, Northeast, South, and Southeast Brazil. Eighteen CYP2D6 alleles were identified in the Brazilian population. The CYP2D6*1 and CYP2D6*2 alleles were the most frequent and widely distributed in different geographical regions of Brazil. The highest number of CYPD6 alleles observed was six and the frequency of individuals with more than two copies ranged from 6.3% (in Southern Brazil) to 10.2% (Northern Brazil). The analysis of molecular variance showed that CYP2D6 is homogeneously distributed across different Brazilian regions and most of the differences can be attributed to inter-individual differences. The most frequent predicted metabolic status was EM (83.5%). Overall 2.5% and 3.7% of Brazilians were PMs and UMs respectively. Genomic ancestry proportions differ only in the prevalence of intermediate metabolizers. The IM predicted phenotype is associated with a higher proportion of African ancestry and a lower proportion of European ancestry in Brazilians. PM and UM classes did not vary among regions and/or ancestry proportions therefore unique CYP2D6 testing guidelines for Brazilians are possible and could potentially avoid ineffective or adverse events outcomes due to drug prescriptions.

Citing Articles

Effects of gene polymorphism on plasma concentration and therapeutic effect of olanzapine.

Yang Y, Liu W, Wu R Heliyon. 2024; 10(7):e28832.

PMID: 38576571 PMC: 10990950. DOI: 10.1016/j.heliyon.2024.e28832.


Association of and Genetic Variants on Primaquine Hemolysis in G6PD-Deficient Patients.

Macedo M, Almeida A, Silva G, Oliveira A, Mwangi V, Shuan A Pathogens. 2023; 12(7).

PMID: 37513742 PMC: 10384057. DOI: 10.3390/pathogens12070895.


Higher-Dose Primaquine to Prevent Relapse of Malaria.

Chamma-Siqueira N, Negreiros S, Ballard S, Farias S, Silva S, Chenet S N Engl J Med. 2022; 386(13):1244-1253.

PMID: 35353962 PMC: 9132489. DOI: 10.1056/NEJMoa2104226.


A Computational Understanding of Inter-Individual Variability in CYP2D6 Activity to Investigate the Impact of Missense Mutations on Ochratoxin A Metabolism.

Dorne J, Cirlini M, Louisse J, Pedroni L, Galaverna G, Dellafiora L Toxins (Basel). 2022; 14(3).

PMID: 35324704 PMC: 8950366. DOI: 10.3390/toxins14030207.


Fluvoxamine for the treatment of COVID-19.

Kim H, Manzi S, Gonzelez-Heydrich J, Picker J Lancet Glob Health. 2022; 10(3):e330.

PMID: 35180410 PMC: 8846602. DOI: 10.1016/S2214-109X(22)00003-1.


References
1.
Schaeffeler E, Schwab M, Eichelbaum M, Zanger U . CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat. 2003; 22(6):476-85. DOI: 10.1002/humu.10280. View

2.
Hudson R . Genetic Data Analysis. Methods for Discrete Population Genetic Data. Bruce S. Weir. Sinauer, Sunderland, MA, 1990. xiv, 377 pp., illus. $48; paper, $27. Science. 1990; 250(4980):575. DOI: 10.1126/science.250.4980.575. View

3.
Bradford L . CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002; 3(2):229-43. DOI: 10.1517/14622416.3.2.229. View

4.
De Leon J, Arranz M, Ruano G . Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med. 2008; 28(4):599-617. DOI: 10.1016/j.cll.2008.05.003. View

5.
Bernal M, Sinues B, Johansson I, McLellan R, Wennerholm A, Dahl M . Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics. 1999; 9(5):657-60. View